Antisense oligonucleotide: A promising therapeutic option to beat COVID-19.
Wiley Interdiscip Rev RNA
; 13(4): e1703, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-2277282
ABSTRACT
The COVID-19 crisis and the development of the first approved mRNA vaccine have highlighted the power of RNA-based therapeutic strategies for the development of new medicines. Aside from RNA-vaccines, antisense oligonucleotides (ASOs) represent a new and very promising class of RNA-targeted therapy. Few drugs have already received approval from the Food and Drug Administration. Here, we underscored why and how ASOs hold the potential to change the therapeutic landscape to beat SARS-CoV-2 viral infections. This article is categorized under RNA Interactions with Proteins and Other Molecules > Small Molecule-RNA Interactions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Oligonucleotides, Antisense
/
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Wiley Interdiscip Rev RNA
Year:
2022
Document Type:
Article
Affiliation country:
Wrna.1703
Similar
MEDLINE
...
LILACS
LIS